SHENZHEN, China, Aug. 21, 2024 /PRNewswire/ -- UTime Limited
(NASDAQ: WTO) ("UTime" or the "Company") is pleased to announce its
ambitious strategy for advancing AI-driven health solutions.
Recognizing the growing value and potential of smart health
technologies, UTime is committing significant investments to expand
its smart medical wearable products business.
In strategic collaboration with Dr. Ehud
Baron, a renowned figure in medical technology innovation,
UTime is set to enhance its offerings in blood pressure measurement
and extend into hemodynamic and health mapping products. Dr. Baron
will collaborate with UTime's team to develop comprehensive plans
for a diverse range of health product lines. The initial focus will
be on optimizing UTime's flagship blood pressure monitoring watch.
Upon successful development, the Company plans to further expand
its product range to address a wide spectrum of smart healthcare
needs.
Additionally, UTime intends to launch a variety of products
focusing on smart detection of key health indicators, such as heart
rate and sleep monitoring devices.
Hengcong Qiu, Chairman of UTime, commented, "We believe that our
strategic cooperation with Dr. Ehud
Baron and our AI-enabled healthcare initiatives will
spearhead key growth opportunities for UTime, positioning us at the
forefront of innovation in the healthcare technology sector."
About UTime Limited
UTime Ltd., established in 2008, provides cost-effective mobile
devices to consumers globally and to help low-income individuals
from established markets, including the
United States and emerging markets to have better access to
updated mobile technology. Since 2024, UTime has been committed to
transforming health and wellness through innovative medical
wearable technologies. By leveraging cutting-edge research and
strategic partnerships, UTime aims to provide effective solutions
for disease prevention and health management on a global scale. For
more information, visit the Company's website
at http://www.utimeworld.com/.
Forward-Looking Statements
Statements in this press release about future expectations,
plans and prospects, as well as any other statements regarding
matters that are not historical facts, may constitute
"forward-looking statements" within the meaning of The Private
Securities Litigation Reform Act of 1995. These statements include,
but are not limited to, statements relating to the ability of the
Company to regain compliance with Nasdaq continued listing
requirements. The words "anticipate," "believe," "continue,"
"could," "estimate," "expect," "intend," "may," "plan,"
"potential," "predict," "project," "should," "target," "will,"
"would" and similar expressions are intended to identify
forward-looking statements, although not all forward-looking
statements contain these identifying words. Actual results may
differ materially from those indicated by such forward-looking
statements as a result of various important factors discussed in
the "Risk Factors" section of the Annual Report in Form 20-F filed
with the SEC on July 30, 2024. Any
forward-looking statements contained in this press release speak
only as of the date hereof, and the Company specifically disclaims
any obligation to update any forward-looking statement, whether as
a result of new information, future events or otherwise.
For more information, please contact:
Eaky Tan
eaky@westock.com
View original
content:https://www.prnewswire.co.uk/news-releases/utime-limited-announces-ambitious-ai-health-strategy-and-strategic-collaboration-302227339.html